Author

M. Biggiogero

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 5

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 5 Approach:experimental assay· 4 Research Focus:cell type annotation· 3 Research Focus:host-pathogen & immune response· 3 Research Focus:cell-cell communication· 2 Research Focus:differential expression· 2 Assay:proteomics· 2 Research Focus:cell signaling & trafficking· 1

Frequent Co-Authors

C. Garzoni· 5 shared A. Ceschi· 3 shared D. Jarrossay· 3 shared P. Ferrari· 3 shared A. A. Shanbhag· 2 shared A. Cassotta· 2 shared A. Franzetti Pellanda· 2 shared A. Franzetti-Pellanda· 2 shared

Activity by Year

2021-2023 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 35 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

5 shared papersImmunology

C. Garzoni

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

Therapeutic and vaccine-induced cross-reactive antibodies with effector function against emerging Omicron variants

A. Addetia, L. Piccoli, J. B. Case, Y.-J. Park, M. Beltramello, B. Guarino, H. Dang, D. Pinto, S. Scheaffer, K. Sprouse, J. Bassi, C. Silacci-Fregni, F. Muoio, M. Dini, L. Vincenzetti, , Fran

The paper shows that cross-reactive antibodies, like S309, retain effector functions against emerging Omicron variants despite reduced neutralization.

bioRxiv · Jan 17, 2023 · PreprintImmunology

Human neutralizing antibodies to cold linear epitopes and to subdomain 1 of SARS-CoV-2

F. Bianchini, V. Crivelli, M. E. Abernathy, C. Guerra, M. Palus, J. Muri, H. Marcotte, A. Piralla, M. Pedotti, R. De, L. Simonelli, M. Matkovic, C. Toscano, M. Biggiogero, V. Calvaruso, , Ru

The paper identifies broadly cross-reactive neutralizing antibodies against SARS-CoV-2 variants using coldspot-guided antibody discovery.

bioRxiv · Nov 24, 2022 · PreprintImmunology

Maturation of SARS-CoV-2 Spike-specific memory B cells drives resilience to viral escape

R. Marzi, J. Bassi, C. Silacci-Fregni, I. Bartha, F. Muoio, K. Culap, N. Sprugasci, G. Lombardo, C. Saliba, E. Cameroni, A. Cassotta, J. S. Low, A. C. Walls, M. McCallum, M. A. Tortorici, , L. Piccoli

The paper examines the kinetics, avidity, and cross-reactivity of SARS-CoV-2-specific memory B cells and antibodies in infected and vaccinated individuals over 16 months, finding that MBC maturation enhances resilience to viral escape.

bioRxiv · Sep 30, 2022Immunology

Anti-chemokine antibodies after SARS-CoV-2 infection correlate with favorable disease course

J. Muri, V. Cecchinato, A. Cavalli, A. A. Shanbhag, M. Matkovic, M. Biggiogero, P. A. Maida, J. Moritz, C. Toscano, E. Ghovehoud, R. Furlan, F. Barbic, A. Voza, G. De Nadai, C. Cervia, , Franzetti-Pelland

The paper finds that anti-chemokine antibodies after SARS-CoV-2 infection correlate with favorable disease outcomes and predict absence of long COVID symptoms.

bioRxiv · May 23, 2022 · PreprintImmunology

Clonal dissection of immunodominance and cross-reactivity of the CD4+ T cell response to SARS-CoV-2

J. S. Low, D. Vaqueirinho, F. Mele, M. Foglierini, M. Perotti, D. Jarrossay, S. Jovic, T. Terrot, A. Franzetti Pellanda, M. Biggiogero, C. Garzoni, P. Ferrari, A. Ceschi, A. Lanzavecchia, A. Cassotta, F. Sallusto

The paper identifies immunodominant and cross-reactive CD4+ T cell epitopes in SARS-CoV-2, showing their recognition in 93% of patients and potential for vaccine design.

bioRxiv · Mar 23, 2021Immunology